Chapter 240 Yibai Single Anti -clinical Data Released
Qingshan Pharmaceutical.
"Zhang, my friend, I haven't seen you for a long time!"
Three days later, Lucas, Vice President of GlaxoSmithk, appeared in Zhang Yang's office.
Zhang Yang's impression of Lucas has always been quite good. The two started from "ITG bone marrow production."
Knowing that Lucas came to visit, he even delayed the morning meeting.
"Lucas, it's a long time since I saw it! I remember that the last time I met was two years ago, but you finally came to see me again!"
"Zhang! I also want to look at you often, but you also know that I was transferred back to the British headquarters from the Asia -Pacific Branch two years ago, so I couldn't visit you in the past two years."
"Haha, I'm afraid it's not entirely the reason? I think it may be that we have not developed a new medicine you are interested in in the past two years?"
Lucast suddenly blushed and hurriedly said:
"Zhang, it's not what you think."
"Haha!"
Zhang Yang laughed, and as soon as he met, he played a semi -true and half -fake joke with Lucas.
In fact, since the moment he received the call of Lucas, he knew the true purpose of Lucas's trip.
But after the joke, he still greeted Lucas to sit down, and directly solved Lucas.
"Take Lucas, I'm just a joke. We are all old friends for many years. I understand your difficulties."
Lucas's face was suddenly happy, and then relieved heavily, and his tone was inspiring:
"Zhang, you can understand that it's really good. I'm not the kind of person you imagined. I really don't have a chance to come to Huaxia!"
"If there is a chance, I will come to see you long ago!"
But saying that he suddenly had a tone, his face still couldn't help but red again:
"But what you said is really right. This time I came to come because of the new medicine you developed ..."
"The headquarters means that I hope to reach the exclusive authorization cooperation with you!"
"Haha!"
Zhang Yang laughed loudly and had to say that Lucas was really cute.
But soon, he converged with laughter and began to fall in the authorized cooperation mentioned in Lucas.
In fact,
It is not surprising that GlaxoSmith is interested in "Ibladder Double Resistance", but ... just after the clinical trial at the beginning of his own side, GlaxoSmithk couldn't wait to talk about cooperation?
"Lucas, to be honest, your company can understand our new medicine‘ Ibabi ’. I can understand it.”
"I thought you came here to understand the situation of 'Yibai Midumi' and understand the real effect of clinical trials. I didn't expect ... Do you want to start talking with us directly and cooperate with us?"
"Are you so confident in us?!"
This remark made Lucas blush again. Similarly, he asked President William three days ago.
However, he naturally couldn't tell Zhang Yang, who was "afraid of being headed by other pharmaceutical companies" by President William.
"Zhang, we must be very confident in you!"
"We believe that this' Ibabi Anti -Anti -Mipida" can definitely pass the clinical trials smoothly, and it will definitely be successfully listed. "
Zhang Yang laughed and didn't think much about it, and said:
"Well, since you all have such a strong confidence, I can't always say no?!"
"Then talk about cooperation matters?"
"Okay!"
Lucas finally relieved in his heart, and he finally took the right track after such a large circle, and hurriedly said:
"Zhang, then let me talk about our thoughts first."
"We hope that as before, we first sign a intention contract. When your new drugs have completed the clinical trial, we will talk about the agency price and regional price of the new drug."
"At the same time, after the straw contract, we immediately launched the clinical trial of this" Yibai Mipide "new drug in Europe. Of course, all clinical trial costs and related work are borne by us, we are responsible!
br>
"Do you think it is okay?"
Zhang Yang nodded slightly.
Qingshan Pharmaceutical and GlaxoSmith are not collaborated once or twice. The previous "liver cell activation agent", "kidney poison clear dialysis needle", is almost all of which cooperate in this way.
Just ...
The clinical trials in Europe felt a bit wrong in Europe.
The previous "liver cell activation agent" and "kidney poisoning dialysis needle" were the complete prescriptions provided by the simulator. Jang Yang naturally had 100%confidence in clinical trials in various places around the world.
He knew that he could be successfully listed after a few times.
But this "Yibai Midumi" is an independent research and development of Qingshan Pharmaceutical R & D Center. How many times will they be modified and how much time to go through the market, he is not sure.
"Lucas, grass signing intention contract, etc. After clinical trials, I talk about the price. I have no opinion!"
"But at present,‘ Yibaiab ’has just conducted a clinical first phase test in our Huaxia. I’ m afraid you need to modify many drug components. If you start clinical trials simultaneously, some waste resources!
"So, after we passed the clinical phase of Huaxia, you will start clinical trials again.
Lucas froze slightly, but nodded slightly when he thought about it.
"Well, what you say makes sense, just follow your plan!"
"Let's sign a intention contract first. When you complete the clinical phase of the clinical period, we will start clinical trials in Europe and strive for the fastest time to introduce Europe!"
"Hmm!"
In the three words, Zhang Yang and Lucas successfully reached a cooperation agreement.
Zhang Yang's face was completely relaxed, and Lucas was also relieved. However, when Zhang Yang was ready to talk to Lucas, Lucas suddenly interrupted:
"By the way, Zhang, another thing I almost forgot."
"Before coming, President William deliberately prepared a gift for you and instructed me to bring you in person!"
"Oh? Gift?!"
Zhang Yang was a little surprised, and then saw Lucas carefully flattened the suitcase he carried, and then slowly took out a slender and exquisite small painting box from the suitcase.
He put the small painting box on the coffee table, and opened the side:
"This is a pair of ancient paintings bought from a collector in the hands of a collector.
"This painting originated from the Song Dynasty. By the Qing Dynasty, it became the collection of the Palace of the Qing Dynasty. Later, a Japanese collector was purchased from the Eight Banners' children to overseas."
"This time, our president specially bought it and gave you as a gift. I hope you can like it."
"Beiqi school book map?"
Zhang Yang was stunned in his heart, and he couldn't help laughing.
To be honest, he didn't even hear the name of this famous painting. However, ... when he heard the collection of the Qing Palace, and the Japanese purchased from the eight -flag's children to overseas, he could not help but have a little interest.
After Lucas carefully opened the axis of about 1 meter long, he was suddenly attracted by the exquisite "Beiqi School Book Picture" in front of him.
Although this ancient painting has gone through a thousand years of vicissitudes, the colors on the scroll are still bright as new and clear.
The most important thing is that the characters on the scroll are different, each of which is lifelike, beautiful and vivid, making people look very comfortable at a glance!
"His ..."
Although Zhang Yang does not understand the collection, this kind of really good thing can see extraordinary at a glance!
"Lucas, this gift is too expensive, I can't accept it!"
"Zhang, not expensive, this is a little bit of our president, as long as you like it!"
"I like it, but I like it ..."
"That's OK!"
Lucas smiled and interrupted Zhang Yang:
"Now that you like it, then if you have any special wanting to collect, you have to collect the calligraphy and paintings, although we tell us that although we are a particularly influential company around the world, in the UK, there are still good connections in Europe. "
There is no mistake, one, one, one, one, one, one, one, one 619, one book, one, one, one, one, one, one, a book!
"Collecting some Huaxia cultural relics is still okay!"
"This ..."
Zhang Yang originally said casually, but did not expect that Lucas would obviously mean that he would make him wrong.
But thinking about it, Gramosk is so diligent that he wants to please himself and facilitates the authorization of more new drugs in the future.
In this case, if they want to send arts and paintings to themselves, it is not a bad thing to make more national treasures that have lost overseas.
"Okay, Lucas, then thank you for your kindness."
"You're welcome, we just have a little heart."
Lucas laughed, and did not expect that it would go so smoothly.
And Zhang Yang's answer also made him determined that Zhang Yang was really interested in Huaxia's cultural relics, and this time, going back can also accurately reply to President William.
Next, Zhang Yang chatted with Lucas for about ten minutes, and then called Ren Xiaomin and Lucas to sign an intention contract.
When Ren Xiaomin took Lucas out of the office, Zhang Yang suddenly thought of Novartis and thought of Friedman.
Two companies with the best cooperation overseas in Qingshan Pharmaceuticals, one is the Grammot of Europe, and the other is Nuohua in the United States.
Novartis has always been in contact with Jewish Friedman.
"I haven't seen Friedman for a long time."
"But this time Lucas came to discuss the cooperation of‘ Ibabi ’. Novartis is definitely interested. Friedman’ s may not be able to come to the door for a long time. "
Zhang Yang made a good expectation of Friedman's door, but this time he expected mistakes.
In the next two or three days, he did not wait to visit Friedman's visit, and did not even receive a call from Friedman.
Just when he was also unexpected, the results of the first batch of double -blind clinical trials of the first batch of "Yibai Mipide" came out.
Zhang Yang quickly focused on the results of the clinical trial of "Ibabi".
This time, "Ibabi" also belongs to the clinical phase of the first and second phases, and a total of 104 subjects were raised.
Because acute leukemia is a major high -risk disease, many of the trials are very critical. After being allowed to be allowed, Director Hu applied for independent administration quota of 32 people, that is, he did not participate in the double -blind test.
The remaining 72 subjects were not too heavy, and they could barely maintain it through the drug. They set up a double -blind test. 36 people became the test team and 36 were listed as a placebo group.
"Boss, the latest 32 independent medication patients have come out, and the treatment effect is worse than we expected."
"First of all, stability. Thousands of animal test data in our laboratory, 'Yibai Mipide' response to leukemia cells in animals has reached more than 75%, and it is applied to the human body ..." >
"In the past, 50%of patients' cell response rates were only 51%, which means that at least half of the leukemia cells in the patient's body were not effectively identified or killed, which was far from our expected treatment effect! "
"Of course, 30%of patients have a response of 70-80%, which basically meet our treatment expectations. Even 5%of patients have a response of 90%. Far exceptional to our imagination "
"This is obviously a strong phenomenon of" individual differences "."
In the office, Zhang Yang carefully listened to Wei Tian's report details.
He frowned slightly, but soon opened it, and this situation was actually in his expected.
The previous "ITG human bone marrow production" and "renal poisoning dialysis needle" can be applied to almost all patients. That is because both drugs are produced by simulator and are real top -line drugs.
The "Yibai Mipide" independently developed by Qingshan Pharmaceutical is obviously not such a level. It is normal for individual differences, side effects, and poor response. This is also a process that all pharmaceutical companies and all drugs must go through.
"Well, except for obvious individual differences, what is the situation of double blindness? What about the universal nature of the drug?"
"The situation of double -blind testing is okay! After a week of medication, we can basically confirm which of the test group and which are the placebo group."
"It can be determined that the generality of the drug is fine. Anyone who uses the medicine has reacted, but the treatment effect is still very large!"
Hearing this, Zhang Yang exhaled gently.
One of the most important evaluation values of a new drug is the generality of the drug.
Strong generality and effectiveness for almost all patients, then prove that the research and development ideas and targets of drugs have taken the right path.
As for the floating factors of the treatment effect, there are many: such as human race differences, differences in condition, and age gender. Next, we must find the influencing factor through treatment differences, and finally adjust the drug component.
"Okay, I know. The first goal of the first project team is to find a way to find the reasons that affect the difference in treatment. Try to adjust the drug component more accurately and stable, and strive to achieve at least 80%of the killing effect!"
"The patients who have 90%of the treatment effect need additional research. See if it is an incidental phenomenon or the specific reason!"
"Okay! I will arrange it."
"Well, what about side effects?"
When it comes to side effects, Wei Tian's face is slightly eased a bit:
"There is no new situation of side effects, and it is basically the same as our previous situation in the laboratory."
"Of course, it may also be that the medication time is too short. After all, it is only a week. Many side effects have not appeared so quickly."
Zhang Yang nodded.
"Well, okay, then you upload the clinical trial data of the first week to the website of the National Clinical Test Center. Many patients pay attention to specific results."
"Okay! I'll upload it here!"
Three hours later, the first week of clinical data of Qingshan Pharmaceutical "Yibai Midumi" was uploaded to the official website of the National Website, and soon attracted a lot of attention.
(End of this chapter)